Print this page
kidney
-
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin Lymphoma -
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin Lymphoma -
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkins Lymphoma.
Protocol: 012406Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin Lymphoma -
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkins Lymphoma.
Protocol: 012406Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin Lymphoma -
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia.
Protocol: 022404-MM1OA-EA02Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy.
Protocol: 022404-MM1OA-S03Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia.
Protocol: 022404-MM1OA-EA02Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia.
Protocol: 022404-MM1YA-S01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy.
Protocol: 022404-MM1OA-S03Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
Phase 3 Randomized, Double-Blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax + Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia.
Protocol: 022501Principal Investigator:
- Xiaoyi Chen
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia.
Protocol: 022404-MM1YA-S01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Phase 3 Randomized, Double-Blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax + Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia.
Protocol: 022501Principal Investigator:
- Xiaoyi Chen
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Protocol: 032501Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Protocol: 032501Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue